I

n another setback to Sanofi (SNY), the Philippine government has suspended clearance for is dengue vaccine and fined the company a symbolic $2,000 for allegedly failing to comply with product-registration terms.

The move comes less than two months after the drug maker caused a public health uproar by reporting that Dengvaxia could worsen — rather than prevent — future cases of the mosquito-borne virus in people who had not previously been infected. Approximately 800,000 children in the Philippines were vaccinated as part of a government-sponsored program.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X